Monday, April 25, 2016

BRIEF-Abbvie receives U.S. FDA approval of supplemental new drug application for Viekira Pak without Ribavirin

* Abbvie receives u.s. Fda approval of supplemental new drug

application for viekira pak (ombitasvir, paritaprevir, and

ritonavir tablets; dasabuvir tablets) without ribavirin in

genotype 1b chronic...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)